OCT

MOST VIEWED

Four retina experts at a Bayer-sponsored aflibercept 8 mg symposium at EURETINA 2026 in Vienna
Posterior Segment

Dry First, Extend Later

Four retina experts on aflibercept 8 mg, from trial data to tough cases Cards on the table, votes in the room and one eye that got away. A competitive Euretina 2026 session tested what really drives aflibercept 8 mg decisions.  Five o’clock on a Friday. The last OCT is loading, the macula looks dry, and...
Hermann grid with grey spots appearing at the intersections of black squares and white corridors
Optics

Anatomy of an Illusion

The optics behind the classics Grey spots that aren’t there, straight lines that lean, and two equal lines that refuse to measure up. Vision scientists explain what classic illusions reveal about the processing between retina and cortex, and why it matters for the patient in your chair. Look at a Hermann grid and ghostly grey...
Illustration of Prof. Timothy Lai piloting a futuristic spacecraft through a colorful, space-like scene
Posterior Segment

The Myopia Wave is Coming for the Macula

Why pathologic myopia deserves a bigger seat at the retina table The world is getting more nearsighted, and the macula is footing the bill. Prof. Timothy Lai maps out what’s coming for retina specialists, and why the response starts years before patients ever reach the retina clinic.  As the global prevalence of myopia continues to...
Retina specialist reviewing OCT imaging while planning personalized treatment for a patient
PIE | Enlightenment

The Road to 2035

What retina experts expect over the next decade The future of retina, according to the people who’ll build it: durability over dosing, phenotypes over diagnosis codes, and a capacity problem nobody’s quite solved yet.  When you’re predicting the future, especially the future of eye care, a crystal ball can be murky and easily misinterpreted. A...
Four speakers presenting career paths for young ophthalmologists at AAO 2026
Beyond the Clinic

Beyond the Clinic: Four Career Paths for Young Ophthalmologists at AAO 2026

From evaluating therapies at the FDA to building medical devices, earning professional trust, and planning for financial independence, young ophthalmologists explored where a clinical career can lead. Dr. Patricia Buehler (United States) could finish a cataract or LASIK case in about 10 minutes. Blepharoplasty took 30 to 40 minutes, she said. She went on to...
An illustration where three people are working together to hold up an eye
Retina

Retinal Innovation: Gene Therapy Meets EU Policy at Euretina 2026

Gene therapy is advancing, but narrow endpoints and fragmented European regulation can still slow the path from promising science to patient care. A retinal therapy can improve sensitivity without moving the visual acuity chart. A clinical trial can be scientifically sound yet nearly fail because of a flawed comparator. And a treatment can exist for...
Day_2_Article_3_16x9
Retina

Beyond the Snapshot: Imaging and AI Rethink Diabetic Retinopathy at Euretina 2026

The diabetic retina can reveal a lot. The trick is knowing which clues matter.  A retinal image can show where diabetic retinopathy (DR) has been. The bigger challenge is finding out where it’s going next.  That question ran through the Modern Imaging and AI in Diabetic Retinopathy: Biomarkers to Bedside session at Euretina 2026 on...
A silhouette with cutouts of puzzlie pieces, eyes, an arrow and a question mark on a blue background
Research

Retinal Disease Masquerades: Diagnostic Traps on Spotlight at Euretina 2026

Six experts shared the floaters, drusen and “classic CSC” that turned out to be something else entirely, and explained how to catch them before they catch you.  A patient with floaters doesn’t always have posterior vitreous detachment. A patient with drusen doesn’t always have age-related macular degeneration (AMD). At Euretina 2026, six specialists spent a...

No entries were found for this taxonomy term.